The independent source for health policy research, polling, and news.
441-460 of 1,311 results
Even before the omicron variant of covid starts to spread widely in the U.S., hospitals are filling up with post-holiday delta cases. Meanwhile, the Supreme Court signals — loudly — that 2022 will be the year it rolls back abortion rights in a big way. Margot Sanger-Katz of The New York Times, Alice Miranda Ollstein of Politico and Mary Ellen McIntire of CQ Roll Call join KHN’s Julie Rovner to discuss these issues and more.
Harm-reduction groups say that requiring a doctor to sign off on their orders of the overdose reversal drug is one of the biggest barriers they face in obtaining the lifesaving medication.
Last week, on the same day the Supreme Court heard a case that could overturn Roe v. Wade, the landmark ruling on abortion rights, Texas enacted a law that creates criminal penalties for anyone who prescribes medication abortions via telehealth or mail.
KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here’s a collection of their appearances.
The promising antiviral drugs to treat covid can halt hospitalizations and deaths, but only if they’re given to patients within three to five days of their first symptoms, a narrow window many people won’t meet. Here’s why.
Federal health officials appear poised to extend a recommendation for covid boosters to all adults, following moves by some governors and mayors to broaden the eligible booster pool as caseloads rise. Meanwhile, the Food and Drug Administration finally has a nominee to head the agency: former FDA chief Robert Califf. And Medicare premiums for consumers will likely rise substantially in 2022, partly due to the approval of a controversial drug to treat Alzheimer’s disease. Tami Luhby of CNN, Sarah Karlin-Smith of the Pink Sheet and Rachel Cohrs of Stat join KHN’s Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Dan Weissmann, host of the “An Arm and a Leg” podcast.
Politicians and many health experts have done their best to see the glass half-full in the plan put forward by congressional Democrats and the president. But it’s “a far cry” from what other nations do to rein in drug prices, and polls show most voters demand more protection.
The number of pharmacies dispensing 340B discounted drugs soared to more than 31,000 this year. Drugmakers struck back by halting some discounts. Hospitals say they are losing millions of dollars — and cutting back services to patients — as a result.
More than 1,000 independent rural pharmacies have closed since 2003, leaving 630 communities with no retail drugstore. As 41 million people stuck in pharmacy deserts make do, the remaining drugstores struggle to survive.
Congress is making slow progress toward completing its ambitious social spending bill, although its Thanksgiving deadline looks optimistic. Meanwhile, a new survey finds the average cost of an employer-provided family plan has risen to more than $22,000. That’s about the cost of a new Toyota Corolla. Alice Miranda Ollstein of Politico, Anna Edney of Bloomberg News and Rebecca Adams of CQ Roll Call join KHN’s Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Rebecca Love, a nurse academic and entrepreneur, about the impending crisis in nursing.
Kids who need a hormone-blocking drug to delay puberty have lost an off-label option. The nearly identical drug the company still sells costs eight times more.
A West Virginia pharmacy cleared a Drug Enforcement Administration investigation. But it shut down anyway, highlighting how the agency’s policies reduce the availability of buprenorphine, an important tool for recovery from opioid addiction.
A last-minute agreement among lawmakers restored a provision seeking to hold down rising costs of prescription medicines. Although details on which drugs will be targeted remain sketchy, the legislation would help patients buying insulin and cap Medicare beneficiaries’ out-of-pocket drug costs at $2,000 a year.
Democratic negotiators on Capitol Hill appear to be nearing a compromise on President Joe Biden’s social spending agenda, spurred partly by Democratic losses on Election Day in Virginia. Meanwhile, the Supreme Court hints it might allow abortion providers to sue Texas over its restrictive new ban. But the relief, if it comes, could be short-lived if the court uses a second case, challenging a law in Mississippi, to weaken or overturn Roe v. Wade. Alice Miranda Ollstein of Politico, Margot Sanger-Katz of The New York Times and Mary Ellen McIntire of CQ Roll Call join KHN’s Julie Rovner to discuss these issues and more. Also this week, Rovner interviews KHN’s Rae Ellen Bichell, who reported and wrote the latest KHN-NPR “Bill of the Month” feature about an emergency bill for a nonemergency birth.
Reports of waning effectiveness and mixed messages about booster shots fuel the politicization of vaccination.
A federal allocation plan meant to ensure equitable distribution of powerful monoclonal antibody treatments for high-risk patients fails to prioritize nursing home residents, a population that remains particularly vulnerable even after vaccination.
President Joe Biden unveiled a compromise “Build Back Better” framework shortly before taking off for key meetings in Europe, but it’s unclear whether the framework can win the votes of all Democrats in the House and Senate, and it leaves out some of the party’s health priorities, notably significant provisions to lower prescription drug prices. Meanwhile, younger children may soon be eligible for covid vaccines. Joanne Kenen of Politico and Johns Hopkins, Sarah Karlin-Smith of the Pink Sheet and Rachana Pradhan of KHN join KHN’s Julie Rovner to discuss these issues and more.
With an eye to shutting down Medicare drug price negotiations, drug companies and their lobbying groups gave roughly $1.6 million in the first six months of 2021, with Democrats edging closer than they have in a decade to Republicans’ total haul.
KHN teamed up with Hulu for a discussion of America's opioid crisis, following the Oct. 13 premiere of the online streaming service’s new series “Dopesick.”
But Americans generally have little confidence that the White House or Congress will recommend the right thing, a new poll shows.
© 2026 KFF